Genetic Analysis

Genetic Analysis (GA), under CEO Ronny Hermansen, reported record sales in Q4 2024, with a 63% increase compared to the previous year, reaching NOK 6.2 million. The company achieved its first positive EBITDA of NOK 0.4 million, marking a significant milestone. The GA-map® Dysbiosis Test sales grew 49% in Q4 and 37% YTD. A major agreement with Ferring Pharmaceuticals was signed to develop a new microbiome-based diagnostic test, targeting a launch in H1 2025. Financial highlights include an operating income of NOK 7.3 million in Q4, with a net loss of NOK 0.9 million. Operating costs decreased by 37% in Q4, attributed to reduced R&D expenses and general cost cuts. Significant events included share purchases by GA’s Head of Operations and CEO, and a collaboration with Ferring Pharmaceuticals to develop a new PCR test. No significant events were reported after the period. GA aims to lead in standardized gut microbiota testing globally.